ASTRAZENECA COMPLETES DIVESTMENT OF CAPRELSA
ASTRAZENECA COMPLETES DIVESTMENT OF RARE DISEASE MEDICINE CAPRELSA AstraZeneca has announced the global completion of the divestment of Caprelsa® (vandetanib), a rare disease medicine, to Genzyme, a Sanofi company. Genzyme made an upfront payment to AstraZeneca of $165 million to acquire the global rights to sell and develop Caprelsa, and will make further development and sales milestone payments of up to $135 million. The transaction does not include the transfer of any AstraZeneca employees or facilities. The divestment reinforces AstraZeneca's strategic focus on its three main